Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2007

View Archived Issues

New therapeutic agents for metabolic disorders described in recent patents

Prime-boost regimens with ALVAC-HIV prime tested in healthy volunteers

Cambria awarded USD 5 million in grants to develop neurodegenerative disease programs

Acrux initiates production of Nicotine MDTS following successful phase I clinical trial

Antisense receives USD 38 million in venture capital from MIG Fonds

Studies support development of REG1 anticoagulation system

GI-5005 yields HCV-specific cellular immune responses in phase Ib study

Echocardiography with perflubutane polymer microspheres accurate in RAMP studies

Noxxon announces R&D alliance with Roche regarding inflammatory diseases

Positive phase III data on adjuvant Avastin treatment in metastatic pancreatic cancer

SynCon flu vaccine protects against a lethal challenge of live virus

Archemix initiates phase IIa ARC-1779 trial in acute coronary syndrome

Bacilligen receives NIH grant to develop improved bladder cancer therapy

Infinity regains worldwide rights for hedgehog pathway inhibitor program

Lundbeck initiates phase I clinical trials with Lu-AA47070 for Parkinson's disease

Plexxikon profiles in vivo antinociceptive efficacy of novel small kinase inhibitor

Novel adenosine A2A receptor antagonist effective in models of Parkinson's disease

Novel histamine H3 receptor antagonist improves cognition in vivo

Pfizer and Nektar confirm Exubera and inhaled insulin product agreement

Preclinical data show multiple mechanisms of action for sonepcizumab

Novel treatment for inflammatory disorders claimed in recent AstraZeneca patent

Recent GSK patent discloses new therapeutic agents for cachexia

UCB to appeal CHMP negative opinion of Cimzia MAA

FDA grants priority review to Abilify sNDA for treatment of bipolar pediatric patients

ViroPharma receives orphan drug designation from the EMEA for Camvia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...